Kimberly-Clark (NYSE:KMB) PT Raised to $136.00

Kimberly-Clark (NYSE:KMB) had its price objective increased by equities researchers at Barclays from $132.00 to $136.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s price objective points to a potential upside of 0.56% from the company’s previous close.

A number of other research firms have also commented on KMB. Piper Sandler raised their price objective on shares of Kimberly-Clark from $145.00 to $152.00 and gave the company an “overweight” rating in a research report on Thursday, March 28th. UBS Group raised their price objective on shares of Kimberly-Clark from $135.00 to $138.00 and gave the company a “neutral” rating in a research report on Wednesday. JPMorgan Chase & Co. raised their price objective on shares of Kimberly-Clark from $115.00 to $123.00 and gave the company an “underweight” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft raised their target price on shares of Kimberly-Clark from $127.00 to $132.00 and gave the company a “hold” rating in a research note on Thursday, March 28th. Finally, The Goldman Sachs Group raised their target price on shares of Kimberly-Clark from $135.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $134.85.

Kimberly-Clark Price Performance

Shares of NYSE:KMB opened at $135.24 on Thursday. The company has a quick ratio of 0.54, a current ratio of 0.81 and a debt-to-equity ratio of 6.05. The firm has a market capitalization of $45.54 billion, a PE ratio of 24.86, a P/E/G ratio of 3.90 and a beta of 0.40. Kimberly-Clark has a twelve month low of $116.32 and a twelve month high of $147.09. The company has a 50-day moving average price of $125.86 and a two-hundred day moving average price of $122.87.

Kimberly-Clark (NYSE:KMB) last released its quarterly earnings data on Tuesday, April 23rd. The company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Kimberly-Clark had a net margin of 9.05% and a return on equity of 250.28%. The company had revenue of $5.15 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same period last year, the business earned $1.67 earnings per share. Kimberly-Clark’s revenue was down .9% compared to the same quarter last year. Equities analysts forecast that Kimberly-Clark will post 6.98 EPS for the current year.

Insiders Place Their Bets

In other Kimberly-Clark news, insider Paula Ramos sold 10,178 shares of Kimberly-Clark stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $137.17, for a total transaction of $1,396,116.26. Following the transaction, the insider now directly owns 795 shares of the company’s stock, valued at $109,050.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Mark T. Smucker bought 827 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were bought at an average cost of $120.98 per share, with a total value of $100,050.46. Following the completion of the purchase, the director now directly owns 827 shares in the company, valued at $100,050.46. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Paula Ramos sold 10,178 shares of Kimberly-Clark stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $137.17, for a total transaction of $1,396,116.26. Following the completion of the transaction, the insider now directly owns 795 shares in the company, valued at $109,050.15. The disclosure for this sale can be found here. Insiders own 0.62% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Conning Inc. increased its stake in shares of Kimberly-Clark by 13.6% in the first quarter. Conning Inc. now owns 302,414 shares of the company’s stock worth $39,040,000 after buying an additional 36,174 shares during the period. Yousif Capital Management LLC increased its stake in shares of Kimberly-Clark by 5.5% in the first quarter. Yousif Capital Management LLC now owns 111,386 shares of the company’s stock worth $14,408,000 after buying an additional 5,835 shares during the period. SlateStone Wealth LLC increased its stake in shares of Kimberly-Clark by 146.2% in the first quarter. SlateStone Wealth LLC now owns 38,928 shares of the company’s stock worth $5,035,000 after buying an additional 23,118 shares during the period. First Personal Financial Services increased its stake in shares of Kimberly-Clark by 0.3% in the first quarter. First Personal Financial Services now owns 40,703 shares of the company’s stock worth $5,265,000 after buying an additional 128 shares during the period. Finally, Mesirow Financial Investment Management Inc. purchased a new position in shares of Kimberly-Clark in the first quarter worth $330,000. 76.29% of the stock is owned by hedge funds and other institutional investors.

Kimberly-Clark Company Profile

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products in the United States. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The company's Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Poise, Depend, Plenitud, Softex, and other brand names.